The Company is constructing its new European humanCEF in Geleen to increase the manufacturing capacity ofChondroCelect in Europe through <strong>TiGenix</strong> B.V.On November 30, 2009, the Company acquired OrthomimeticsLimited. Orthomimetics Limited designs, develops andmanufactures novel, bioresorbable implants for theregenerative repair of articular joint damage resulting fromsports injuries and other trauma. Orthomimetics Limited hasbeen renamed to <strong>TiGenix</strong> Ltd.On July 8, <strong>2010</strong>, the Company has spun off drug discoveryassets to the Dutch company Arcarios B.V. (formerly namedTherosteon B.V.) in which the Company holds a 13.86% equitystake.On the Contribution Date, the Company acquired Cellerix.Cellerix is a Spanish cell therapy company that was foundedin 2004 as a spin-off from the Genetrix Group. Cellerix has aclinical stage pipeline of cell-based products for indicationsof inflammatory and autoimmune origin. Further details onCellerix are provided in section 6.14 of the prospectus.<strong>TiGenix</strong> NV100% 100% 100% 13.86% 100%<strong>TiGenix</strong> Inc.<strong>TiGenix</strong> B.V.<strong>TiGenix</strong> Ltd.Arcarios B.V.Cellerix S.A.4.4 Share capital and shares4.4.1 Share capital and SharesOn the date of publication of this prospectus, the Company’sregistered capital amounts to €74,243,046.23, represented by75,935,556 common Shares without nominal value. The capitalis fully paid up.The table below provides an overview of the history of theCompany’s share capital since its incorporation in 2000. Theoverview should be read together with the notes set outbelow the table.77 •
DateINCORPORATIONFebruary 21,2000TransactionIncorporation (1)Number and classof Shares issued85,800 Class A50,000 Class B14,200 Class CIssuance priceper Share (€)(incl. issuancepremium)Capitalincrease (€)Sharecapital aftertransactionAggregatenumberof Sharesafter capitalincrease€1.00 €150,000.00 €150,000.00 150,000PHASE I CAPITAL ROUNDMarch 13, 2000 Capital increase in cash (2) 364,200 Class A€1.00 €425,000.00 €575,000.00 575,00060,800 Class CMarch 22, 2001 Capital increase in cash (3) 150,000 Class A€1.25 €320,000.00 €895,000.00 895,00040,000 Class B100,000 Class C30,000 Class DPHASE II CAPITAL ROUND - EXERCISE OF WARRANTSSeptember 15,2003Capital increase in cash (4) 4,049,383 Class E €1.00 €4,049,383.00 €4,944,383.00 4,944,383September 15,2003September 15,2003Capital increase in kind (5)Conversion of 200,000 profitcertificates (incorporation of issuancepremiums) (6)290,896 Class A394,106 Class C175,000 Class B25,000 Class C€1.55 €685,002.00 €5,629,385.00 5,629,385€1.00 €200,000.00 €5,829,385.00 5,829,385September 30,Capital increase in cash (7) 1,518,519 Class E €1.00 €1,518,519.00 €7,347,904.00 7,347,9042003May 14, 2004 Capital increase in cash (8) 1,358,024 Class E €3.00 €1,358,024.00 €8,705,928.00 8,705,928April 20, 2005 Capital increase in cash (9) 452,680 Class E €3.00 €452,680.00 €9,158,608.00 9,158,608August 23,2005November 3,2005Capital increase in cash pursuantto the exercise of 3 “adjustment”warrants (10)11,762 Class A15,935 Class Cexercise price of€0.01 per warrantCapital increase in cash pursuant to 22,500 Class D exercise price ofthe exercise of 22,500 warrants (11) €1.25 per warrantPHASE III CAPITAL ROUND - EXERCISE OF WARRANTSNovember 3,Capital increase in cash (12)2005April 20, 2006October 31,2006114,285 Class A57,142 Class C4,374,282 Class ECapital increase in cash pursuant tothe exercise of 27,500 warrants (13) 27,500 Class D exercise price of€1.25 per warrantCapital increase in cash pursuant to 375,000 Class B exercise price ofthe exercise of 375,000 warrants (14) €1.00 per warrant€0.03 €9,158,608.03 9,186,305€22,432.50 €9,181,040.53 9,208,805€3.50 €4,532,071.91 €13,713,112.44 13,754,514€27,417,50 €13,740,529.94 13,782,014€375,000.00 €14,115,529.94 14,157,014PHASE IV CAPITAL ROUND - EXERCISE OF WARRANTSMarch 27, 2007 Capital increase in cash(15) 8,000,000 €5.00 €7,976,000.00 €22,091,529.94 22,157,014March 27, 2007Capital increase in cash1,200,000 exercise price of €1,196,400 €23,287,929.94 23,357,0141,200,000 over‐allotment warrants (16)pursuant to the exercise of€5.00 per warrantMarch 27, 2007 Capital increase in cash pursuantto the exercise of 494,065 existingshareholder warrants (17 )494,065 exercise priceof €0.01 and€0.001 per warrant€494.47 €23,288,424.41 23,851,079April 17, 2008October 13,2008April 23, 2009Capital increase in cash pursuant tothe exercise of 603,910 warrants (18)603,910 exercise price of€1.00 and €3.00 perwarrantCapital increase in cash pursuant tothe exercise of 109,500 warrants (19) 109,500 exercise price of€3.00 per warrantCapital increase in cash pursuant to6,790 exercise price ofthe exercise of 6,790 warrants (20) €3.00 per warrant€603,910 €23,892,334.41 24,454,989€109,500 €24,001,834.41 24,564,489€6,790 €24,008,624.41 24,571,279PHASE V CAPITAL ROUNDJune 26, 2009 Capital increase in cash (21) 1,080,000 €5.00 €1,058,400 €25,067,024.41 25,651,27978 • <strong>TiGenix</strong> • Rights Offering
- Page 2 and 3:
TiGenix NV(Public limited liability
- Page 4 and 5:
Table of ContentsSummary ..........
- Page 7 and 8:
3.7.1 Categories of potential inves
- Page 9 and 10:
5.7.1 Shares and warrants held by i
- Page 11 and 12:
7.5.2 Taxation.....................
- Page 13 and 14:
SummaryThe words written in capital
- Page 15 and 16:
Activities and strategy of the Comp
- Page 17 and 18:
• Two allogeneic adult stem cell
- Page 19 and 20:
• TiGenix’ success depends on i
- Page 22 and 23:
Unaudited pro forma income statemen
- Page 24 and 25:
Recent developmentsAcquisition of C
- Page 26 and 27:
In this context, we would like to s
- Page 28 and 29:
Announcement of the results of theO
- Page 30 and 31:
After the Contribution andafter the
- Page 32 and 33:
ContributionContribution AgreementC
- Page 34 and 35:
Risk factorsAny investment in the P
- Page 36 and 37:
commercialisation of ChondroCelect,
- Page 38 and 39: in delays in bringing products to t
- Page 40 and 41: The Company cannot predict what eff
- Page 42 and 43: y each of its patents and patent ap
- Page 44: to exercise preferential subscripti
- Page 47 and 48: this prospectus which is capable of
- Page 49 and 50: • investment professionals fallin
- Page 51 and 52: 1. General information and informat
- Page 53 and 54: 1.4.2 Company documents and otherin
- Page 55 and 56: • the granting of discharge of li
- Page 57 and 58: • in case of registered Shares, t
- Page 59 and 60: cast at the meeting. If the amount
- Page 61 and 62: No one may cast a greater number of
- Page 63 and 64: If a Belgian resident individual ne
- Page 65 and 66: Belgium has concluded tax treaties
- Page 67 and 68: 3. Information on the Contributiona
- Page 69 and 70: In this context, we would like to s
- Page 71 and 72: TiGenix has a limited financial deb
- Page 73 and 74: Thousands of Euro (€) TiGenix Cel
- Page 75 and 76: 3.5.2 Issuance Price and RatioThe i
- Page 77 and 78: (c)Rules for subscriptionSubject to
- Page 79 and 80: The Scrips Private Placement will o
- Page 81 and 82: to comply with any of its obligatio
- Page 83 and 84: 3.11.2 Scenario 1: Existing Shareho
- Page 85 and 86: • a pledge of Locked Shares to a
- Page 87: 4. General information about THECOM
- Page 91 and 92: Upon completion of the IPO of TiGen
- Page 93 and 94: Issue dateMay 14,2004April 20,2005T
- Page 95 and 96: 4.7.2 Voting rightsAs further descr
- Page 97 and 98: can be obtained free of charge at t
- Page 99 and 100: 5.2.4 Composition of the Board of D
- Page 101 and 102: Amonis. Mr. Duron has been CEO of K
- Page 103 and 104: 5.3.4 Nomination and remunerationco
- Page 105 and 106: • investor relations: nurturing c
- Page 107 and 108: The remuneration of the members of
- Page 109 and 110: 5.7.2 Shares and warrants held by e
- Page 111 and 112: Cellerix EBIP 2010An EBIP for senio
- Page 113 and 114: The minutes must also contain a jus
- Page 115 and 116: 6. Activities of Tigenix andits sub
- Page 117 and 118: • Clinical stage pipeline. TiGeni
- Page 119 and 120: 6.3.3 Acquisition of CellerixAs a r
- Page 121 and 122: Full thickness articular cartilage
- Page 123 and 124: Fig. 6.2: Autologous Chondrocyte Im
- Page 125 and 126: Preclinical work in a meniscus repa
- Page 127 and 128: The Company is also ensuring high q
- Page 129 and 130: Recognising the importance of pre-l
- Page 131 and 132: In Spain, since the passage of Orde
- Page 133 and 134: Fig. 6.6: ChondroMimetic procedure
- Page 135 and 136: 6.5.3 Commercial strategyBuilding o
- Page 137 and 138: 6.7 Manufacturing & logisticsEffici
- Page 139 and 140:
The international application WO06/
- Page 141 and 142:
ChondroMimetic competitionThe main
- Page 143 and 144:
in Cellerix’ GMP facility in Madr
- Page 145 and 146:
6.14.3 History and development of C
- Page 147 and 148:
The table below gives an overview o
- Page 149 and 150:
Prevalence No. of cases (2010) Esti
- Page 151 and 152:
Fig. 6.9: Platform development stra
- Page 153 and 154:
In developing Cx601, Cellerix has b
- Page 155 and 156:
6.14.6 Manufacturing & logisticsCel
- Page 157 and 158:
population, methods for the isolati
- Page 159 and 160:
• Cimzia (certolizumab) - UCB: Al
- Page 161 and 162:
Spanish Ministry of Education and S
- Page 163 and 164:
7.2 Consolidated income statementTw
- Page 165 and 166:
7.3.1.2 Research and development ex
- Page 167 and 168:
7.3.2.3 Selling, general and admini
- Page 169 and 170:
7.4.1 Cash flows from operating act
- Page 171 and 172:
Cash & cash equivalents and intangi
- Page 173 and 174:
As of December 31, 2010, the Group
- Page 175 and 176:
8. Consolidated Financial informati
- Page 177 and 178:
8.1.3 Consolidated cash flow statem
- Page 179 and 180:
8.1.5 Notes to consolidated financi
- Page 181 and 182:
operating results and operating pla
- Page 183 and 184:
The Group does not account for work
- Page 186 and 187:
8.1.5.4 Operating result (EBIT)Resu
- Page 188 and 189:
8.1.5.7 TaxesThere is no current ta
- Page 190 and 191:
8.1.5.10 Tangible assetsThousands o
- Page 192 and 193:
8.1.5.14 Deferred charges & accrued
- Page 194 and 195:
8.1.5.18 Finance lease obligations
- Page 196 and 197:
Business combination Cellerix SADes
- Page 198 and 199:
Weighted averageexercise priceTOTAL
- Page 200 and 201:
the respective issue date of the wa
- Page 202 and 203:
Transactions with non-executive dir
- Page 204 and 205:
8.1.5.28 Subsequent eventsAcquisiti
- Page 206 and 207:
8.1.5.31 Disclosure under Article 1
- Page 208 and 209:
Additional statementsThe preparatio
- Page 210 and 211:
9.1.2 Stand-alone balance sheetYear
- Page 212 and 213:
9.1.4 Stand-alone statement of chan
- Page 214 and 215:
) Standards and interpretations iss
- Page 216 and 217:
The clinical development of new dru
- Page 218 and 219:
future against which they may be ap
- Page 220 and 221:
Cellerix’ research and developmen
- Page 222 and 223:
YearThousandsof Euro2010 2009 2008E
- Page 224 and 225:
Thousands of Euro (€)Laboratoryeq
- Page 226 and 227:
Current financial assetsShown below
- Page 228 and 229:
At December 31, Cellerix’ share c
- Page 230 and 231:
9.1.5.17 Deferred revenueThe balanc
- Page 232 and 233:
9.1.5.21 Share-based paymentsThe EB
- Page 234 and 235:
GrantsCellerix received several gra
- Page 236 and 237:
10. Report regarding unaudited prof
- Page 238 and 239:
EMAFDAFibrous tissueGCPGMPGrowth fa
- Page 240 and 241:
Appendix 1: Press releases 2006-201
- Page 242 and 243:
Appendix 2: REGULATORY APPROVALPROC
- Page 244 and 245:
like ChondroCelect or the future ce
- Page 246 and 247:
TitleCountry/regionPatent/applicati
- Page 248 and 249:
TitleCountry/regionPatent/applicati
- Page 250 and 251:
Title“Cell populations having imu
- Page 252 and 253:
D. Trademarks of CellerixThe table
- Page 254 and 255:
Decision resources.Dell’Accio, F.
- Page 256 and 257:
Noyes, F. R., Barber-Westin, S. D.,
- Page 258 and 259:
Appendix 5: 2008, 2009 and2010 mana
- Page 260 and 261:
Contents1. The year in brief ......
- Page 262 and 263:
2. Financial informationa. The Inco
- Page 264 and 265:
The Directors shall call a Sharehol
- Page 266 and 267:
• Exercise price changed to 5.291
- Page 268 and 269:
10 • TiGenix • Rights Offering
- Page 270 and 271:
Contents1. The year in brief ......
- Page 272 and 273:
3. Financial informationa. The Inco
- Page 274 and 275:
Exceptionally, for the following re
- Page 276 and 277:
(d)(e)Duration: The Options Plan wi
- Page 278 and 279:
Contents1. The year in brief ......
- Page 280 and 281:
3. Financial informationa. The Inco
- Page 282 and 283:
eceipt sent to the number or addres
- Page 284 and 285:
THE COMPANYTiGenix NVRomeinse straa